Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia
About this trial
This is an interventional diagnostic trial for Alzheimer Disease focused on measuring Neurodegenerative disease, Elderly, Dementia, FDG-PET, MRI, Neuroimaging
Eligibility Criteria
Inclusion Criteria:
- Age: over 65
- Participants (or representatives) gave their written informed consent
- Dementia diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria
- For Alzheimer arm: probable Alzheimer based disease according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association ) criteria
- For vascular dementia: diagnosis based on NINDS-AIREN (National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences) criteria
- For MCI: diagnosis based on Petersen index
Exclusion Criteria:
- Claustrophobia
- Diabetes
- Cardiovascular disease
- Glycemia over 1.3 g/L
- Lumbar puncture within one week before MRI examination
- Non MR-compatible implant
- Suspected brain metastases
- No informed consent signature
Sites / Locations
- CHU Rouen
- CHU Amiens
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
Alzheimer
Vascular dementia
Mild cognitive impairment (MCI)
Healthy subjects (MRI)
Healthy subjects (PET)
Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
Healthy subjects agreeing to undergo magnetic resonance imaging examination.
Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.